Raymond James Financial Inc. Acquires Shares of 26,916 Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Raymond James Financial Inc. acquired a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) during the 4th quarter, Holdings Channel reports. The firm acquired 26,916 shares of the company’s stock, valued at approximately $224,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its position in Zevra Therapeutics by 10.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 121,356 shares of the company’s stock worth $842,000 after acquiring an additional 11,038 shares during the period. State Street Corp grew its position in shares of Zevra Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 772,825 shares of the company’s stock worth $5,363,000 after purchasing an additional 52,966 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Zevra Therapeutics during the third quarter worth approximately $94,000. Barclays PLC raised its position in shares of Zevra Therapeutics by 292.6% in the third quarter. Barclays PLC now owns 57,599 shares of the company’s stock valued at $399,000 after buying an additional 42,926 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after buying an additional 129,600 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ZVRA shares. Guggenheim increased their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Canaccord Genuity Group increased their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. JMP Securities set a $18.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Zevra Therapeutics presently has an average rating of “Buy” and a consensus price target of $22.29.

Insider Activity at Zevra Therapeutics

In related news, CEO Neil F. Mcfarlane sold 61,273 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the sale, the chief executive officer now owns 222,060 shares in the company, valued at $1,745,391.60. The trade was a 21.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares of the company’s stock, valued at $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 85,773 shares of company stock valued at $674,176 in the last quarter. Insiders own 2.40% of the company’s stock.

Zevra Therapeutics Price Performance

Shares of ZVRA stock opened at $6.90 on Friday. The business has a fifty day simple moving average of $7.67 and a 200 day simple moving average of $8.14. The company has a market cap of $373.40 million, a P/E ratio of -3.50 and a beta of 1.94. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. On average, sell-side analysts forecast that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.